First Amendment to Research, Development and Commercialization Collaboration Agreement between Samaritan Pharmaceuticals, Inc., Samaritan Pharmaceuticals Ireland Ltd., and Pharmaplaz Ltd.
Samaritan Pharmaceuticals, Inc., Samaritan Pharmaceuticals Ireland Ltd., and Pharmaplaz Ltd. have agreed to amend their existing collaboration agreement. The amendment extends the due date for a scheduled payment (Payment 2) from September 16, 2007, to October 16, 2007. All other terms of the original agreement remain unchanged. The amendment is effective upon signing by authorized representatives of all parties.
FIRST AMENDMENT TO THE AGREEMENT BETWEEN SAMARITAN PHARMACEUTICALS, INC. AND SAMARITAN
PHARMACEUTICALS IRELAND LTD., AGREEMENT WITH PHARMAPLAZ LTD., RESEARCH, DEVELOPMENT AND
COMMERCIALIZATION COLLABORATION AGREEMENT
This First Amendment to Agreement is entered into by and between Samaritan Pharmaceuticals, Inc. and Samaritan Pharmaceuticals Ireland Ltd (“Samaritan”) with Pharmaplaz Ltd. (“Pharmaplaz”), dated March 9, 2007. In consideration of the mutual undertakings and covenants hereinafter set forth, the PARTIES agree as follows:
WHEREAS, under the Agreement, Payment 2 is due September 16, 2007.
NOW, THEREFORE BE IT RESOLVED THAT, the PARTIES approve and authorize the Amendment to Agreement to extend the payment date of Payment 2 for 30 days to October 16, 2007.
All other terms and conditions not expressly amended herein, shall remain in full force and effect.
This First Amendment to Agreement is signed below by the duly authorized representatives of the PARTIES.
AGREED:
PHARMAPLAZ
By: /s/ Michael J. Macken Date: September 20, 2007
—
Michael J. Macken, CEO
SAMARITAN PHARMACEUTICALS, INC.
By: /s/ Dr. Janet Greeson Date: September 20, 2007
—
Dr. Janet Greeson, CEO
SAMARITAN PHARMAEUTICALS IRELAND, LTD.
By: /s/ Eugene Boyle Date: September 20, 2007
—
Eugene Boyle, CFO
